Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Almonty Announces Intention to Relocate to the United States (click to learn more) Benton Intersects 22.0 m Grading 7.47% Copper Including 8.0 m Grading 11.93% Copper (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Marker Therapeutics Inc MRKR

Healthcare Biotechnology
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:MRKR)

Marker Therapeutics Announces $16.1 Million Private Placement

GlobeNewswire December 19, 2024

Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma

GlobeNewswire December 19, 2024

Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer

GlobeNewswire December 17, 2024

Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium

GlobeNewswire December 10, 2024

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

GlobeNewswire November 26, 2024

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire November 14, 2024

Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors

GlobeNewswire August 28, 2024

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire August 14, 2024

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma

GlobeNewswire August 12, 2024
View More News ››

Opinion & Analysis (NDAQ:MRKR)

Interim Data Indicate Multiantigen Cell Therapy in Solid Tumors 'Just Might Work'

Streetwise Reports July 24, 2019
View More Opinion ››

Bullboard Posts (NDAQ:MRKR)

Marker Therapeutics Awarded $9.5 Million Grant from the Canc

News; $MRKR Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to...
whytestocks - December 17, 2024

Marker Therapeutics, Inc. (MRKR): Navigating the Complexitie

http://beyondspx.com/2024/07/31/marker-therapeutics-inc-mrkr-navigating-the-complexities-of-immuno-oncology-2/
MikeTester - August 2, 2024

Principal Investigator from City of Hope National Medical Ce

Breaking News: $MRKR Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker...
whytestocks - April 8, 2024

I've heard of this company

The Mayo Clinic has gotten DOD grant and they are working on some vacines. 
Carver78 - March 21, 2017

heavy volume and price up

Well, today we had 4.7 million shares trade(14.4% of total outstanding shares), and a price increase of 31.18%.  It appears that...
thlove - May 11, 2015

Another Thursday trade with Profit on Friday

This was another trade that was mentioned on my blog about being patient and having the discipline to wait fro the trade to happen and...
Pennystockformula - November 23, 2013
View more Bullboard ››

Interactive Capital Partners Corporation

Interactive Capital Partners Corporation

View More »